Haute-Garonne
Quiénes somos
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors
